Retatrutide, a novel dual-action glucose-dependent insulinotropic polypeptide receptor activator read more developed by Alluvi Healthcare, is creating considerable buzz within the medical community as a promising advancement in weight loss. Initial trial data demonstrate a significant influence on body weight, often surpassing current existing ther